[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"congestion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:congestion":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,84,119,150,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100643108","sure-hf-urinary-sodium-guided-diuretic-therapy-in-heart-failure-100643108",false,"NCT07631780","SURE-HF: Urinary Sodium-Guided Diuretic Therapy in Heart Failure","Urinary Sodium-Guided Optimization of Diuretic Therapy in Patients With Worsening Heart Failure: Rationale and Design of a Pragmatic Randomized Controlled Trial (SURE-HF Trial)","SURE-HF","Inclusion Criteria:\n\n* Age ≥18 years.\n* Confirmed diagnosis of worsening heart failure (WHF), characterized by symptoms and signs of acute decompensation requiring hospitalization for intensification of intravenous diuretic therapy.\n* Previous intake of a loop diuretic (torasemide or furosemide) in any dose for at least 2 days before hospitalization.\n* Presence of clinical signs and symptoms of congestion (e.g., dyspnea, orthopnea, peripheral edema, pulmonary congestion).\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Acute coronary syndrome within the previous 30 days.\n* Acute heart failure requiring urgent invasive intervention, including cardiogenic shock or mechanical circulatory support.\n* Current admission to an intensive care unit.\n* Systolic blood pressure ≤90 mmHg or requirement for inotropic\u002Fvasopressor support.\n* Recent use (≤48 hours) of inotropic agents affecting fluid and electrolyte balance.\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m² or requirement for renal replacement therapy.\n* Hypokalemia (\\\u003C3.5 mmol\u002FL) or hyperkalemia (≥5.5 mmol\u002FL).\n* Clinically significant hyponatremia (\\\u003C130 mmol\u002FL) or hypernatremia (\\>150 mmol\u002FL).\n* Significant comorbidities affecting sodium-water balance (e.g., liver cirrhosis with ascites, nephrotic syndrome, severe infection or sepsis).\n* Pregnancy or breastfeeding.\n* Active malignancy.\n* Inability to comply with the study protocol or participation in another interventional clinical trial.","ALL","18 Years",{"count":20,"type":21},260,"ESTIMATED","INTERVENTIONAL",[24],"NA","The SURE-HF trial is a pragmatic, multicentre, randomized controlled study evaluating natriuresis-guided optimization of intravenous loop diuretic therapy in patients hospitalized with worsening heart failure (WHF). The study aims to determine whether serial urinary sodium assessment combined with a structured decongestive treatment algorithm improves decongestion, reduces the need for therapy escalation, and enhances discharge readiness compared with standard care.\n\nParticipants will be randomized to standard urine output-guided therapy or natriuresis-guided decongestive strategies using different intravenous loop diuretic administration regimens. The study integrates bedside diagnostic tools including lung ultrasound, inferior vena cava assessment, focused echocardiography, and serial clinical congestion monitoring.\n\nThe primary endpoint is a hierarchical composite outcome including escalation of heart failure therapy, persistent congestion at discharge, inability to transition to oral loop diuretics by Day 5, and residual ultrasound congestion. The findings of the SURE-HF trial may support implementation of urinary sodium-guided and ultrasound-assisted decongestive therapy in routine heart failure management.",[27,28,29],"Worsening Heart Failure","Congestion","Heart Failure",[27,28,31,32,33,34,35,36,37],"Natriuresis","Urinary Sodium","Diuretic Therapy","Loop Diuretics","Decongestion","Fluid Overload","Bedside Diagnostics","NOT_YET_RECRUITING","2026-06-01",{"date":41,"type":42},"2026-06-08","ACTUAL",{"date":44,"type":21},"2026-06",{"date":46,"type":21},"2027-12",{"name":48,"class":49},"Nurgul Ablakimova","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100637510","urinary-chloride-and-sodium-changes-and-residual-congestion-in-acute-heart-failure-100637510","NCT07597512","Urinary Chloride and Sodium Changes and Residual Congestion in Acute Heart Failure","Association of Urinary Chloride and Sodium Dynamics With Multiparametrically Assessed Residual Congestion in Acute Heart Failure (CLORINA-IC)","CLORINA-IC","Inclusion Criteria:\n\n* Provision of written informed consent prior to any study-related procedures;\n* Age ≥ 18 years;\n* Episode of AHF requiring hospital admission and treatment with intravenous furosemide;\n* New York Heart Association (NYHA) functional class II-IV;\n* NT-proBNP \\>1000 pg\u002FmL or BNP \\>250 pg\u002FmL, measured within a period not exceeding 24 hours prior to inclusion;\n* Transthoracic echocardiogram performed within the previous 24 months. All LVEF categories will be included: reduced LVEF (\\\u003C40%), mildly reduced LVEF (41-49%), and preserved LVEF (≥50%). In patients with preserved LVEF (HFpEF), congruent structural and\u002For functional echocardiographic abnormalities are required (left ventricular hypertrophy defined as septal or posterior wall thickness ≥11 mm, E\u002Fe' \\>9, or left atrial volume \\>32 mL\u002Fm²);\n* Signs of fluid overload, with at least two of the following: jugular venous distension (at least up to the sternocleidomastoid level, \\~10 cm), lower limb edema, ascites, or pleural effusion confirmed by chest radiography or lung ultrasound\n* Treatment with oral furosemide at a dose of at least 40 mg\u002Fday within the previous month.\n\nExclusion Criteria:\n\n* Symptomatic hyponatremia or plasma sodium level ≤125 mmol\u002FL;\n* Hemoglobin \\\u003C9 g\u002FdL;\n* Hypokalemia: serum potassium \\\u003C3 mEq\u002FL;\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73 m²;\n* Hemodynamic instability at admission, defined as symptomatic hypotension;\n* Acute coronary syndrome, cardiogenic shock, or admission to the intensive care unit (ICU);\n* Severe infection (e.g., pneumonia, sepsis, leukocyte count ≥12,000\u002FμL, C-reactive protein \\>50 mg\u002FL, or positive COVID-19 test);\n* Requirement for inotropic agents;\n* Life expectancy \\\u003C3 months or, in the investigator's judgment, inability to comply with study procedures.",{"count":60,"type":21},223,"OBSERVATIONAL","The goal of this observational study is to learn how changes in urinary sodium and chloride levels relate to fluid overload and short-term outcomes in patients hospitalized with acute heart failure (AHF). The main questions it aims to answer are:\n\n* Do changes over time in urinary sodium and chloride reflect how well excess fluid is being removed during hospitalization?\n* Are these changes associated with residual congestion at discharge and with the risk of worsening heart failure or death after discharge?\n\nParticipants hospitalized for AHF and treated with intravenous diuretics as part of their usual care will have clinical assessments, blood and urine tests, and echocardiographic evaluations collected at several time points during their hospital stay. Researchers will also record clinical outcomes, including worsening heart failure or death, at 30 days and 3 months after discharge.",[64,29,28],"Acute Heart Failure (AHF)",[66,67,68,28,69,70,71,72,73],"Acute Heart Failure","Heart failure","Biomarkers","Urinary chloride","Urinary sodium","Diuretics","point of care ultrasound","POCUS","2026-05-19",{"date":76,"type":42},"2026-05-22",{"date":78,"type":21},"2026-05",{"date":80,"type":21},"2028-12-31",{"name":82,"class":49},"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal",4,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":50},"100634598","training-medical-residents-in-the-use-of-the-venous-excess-ultrasound-vexus-score-for-bedside-volume-assessment-100634598","NCT07541768","Training Medical Residents in the Use of the Venous Excess UltraSound (VExUS) Score for Bedside Volume Assessment.","Training Medical Residents in the Use of the Venous Excess UltraSound (VExUS) Score for Bedside Volume Assessment: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Medical residents in general internal medicine\n* Basic ultrasound skills (POCUS component 1 or ≥200 scans)\n* Working at study site during study period\n\nExclusion Criteria:\n\n* SGUM certification in abdominal ultrasound\n* Advanced duplex ultrasound experience\n* Prior vascular\u002Fduplex training",true,{"count":93,"type":21},23,[24],"This randomized controlled trial evaluates the effectiveness of two training approaches (in-person versus remote) for teaching medical residents to apply the Venous Excess Ultrasound (VExUS) score for bedside volume assessment in patients with acute heart failure. Resident performance will be compared to that of expert physicians certified in abdominal and duplex sonography.",[64,97,28,98],"Fluid Over-load","Congestion, Venous",[100,101,102,73,103,104,105,106,107,108],"Vexus","Venous Excess Ultrasound","Point-of-Care Ultrasound","Ultrasound Training","Medical Education","Volume Assessment","Venous Congestion","Duplex Ultrasound","Bedside Ultrasound","RECRUITING","2026-04-16",{"date":112,"type":42},"2026-04-21",{"date":114,"type":42},"2026-03-20",{"date":116,"type":21},"2026-12-31",{"name":118,"class":49},"Insel Gruppe AG, University Hospital Bern",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":136,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":148,"locationsCount":50},"100577562","optimization-of-fluid-balance-guided-by-bioelectrical-impedance-analysis-in-patients-undergoing-continuous-renal-replacement-therapy-in-critical-care-100577562","NCT06799910","Optimization of Fluid Balance Guided by Bioelectrical Impedance Analysis in Patients Undergoing Continuous Renal Replacement Therapy in Critical Care","OBHIMER","Inclusion Criteria:\n\n* Age \\> 18 years\n* The patient was hospitalized in the intensive care unit of Amiens-Picardie University Hospital.\n* Patient with an increase in fluid balance (TBW \\> 5%)\n* Patient receiving continuous veno-venous hemofiltration (CVVH) on a PrismaFlexR or PrisMaxR machine, initiated due to oliguria, potassium level \\> 6.5 mmol\u002FL, urea level \\> 25 mmol\u002FL, or creatinine \\> 300 µmol\u002FL and severe metabolic acidosis (pH \\\u003C 7.2).\n* Hemodynamically stable patient with a mean arterial pressure (MAP) \\> 65 mmHg for more than 4 hours with norepinephrine.\n* Signed consent to participate in the study by the patient or, if unconscious, their legal representative\u002Fnext of kin.\n\nExclusion Criteria:\n\n* Invalid BIA measurements\n* Internal device powered by an electrical current (pacemaker, implantable cardioverter-defibrillator, neurostimulator)\n* Cardiac arrhythmia (atrial fibrillation, atrial flutter) present at the inclusion\n* Chronic dialysis patient\n* Moribund patient\n* The patient is on extracorporeal mechanical support\n* Hemorrhagic shock\n* Pregnant woman\n* Patient under guardianship or conservators.",{"count":127,"type":21},60,[24],"In critical care, hemodynamic instability often requires volume expansion to restore tissue perfusion, increasing fluid balance and TBW, factors associated with higher mortality. Excess fluid leads to organ dysfunction due to venous congestion, making fluid removal crucial. When diuretics fail, RRT, typically through continuous renal replacement therapy (CRRT), is recommended. However, prescribing the correct level of UF is challenging; insufficient UF can worsen edema, while excessive UF risks hemodynamic instability. This pilot, single-center, prospective, interventional, randomized, controlled, open-label study includes two parallel groups: a standard group with UF prescribed by the physician based on clinical and hemodynamic status and an experimental group with UF guided by the extracellular to total body water (ECW\u002FTBWat) ratio measured by BIA. The aim is to determine if ECW\u002FTBW-guided UF improves fluid and TBW reduction over a 72-hour RRT period.",[28,131,132,133,134,71,135],"RRT","UF","Bio-impendance Analysis","Fluid Removal","Overload",[137,138,139,140,141,131,132],"bio-impendance analysis","fluid removal","diuretics","overload","congestion","2025-01-28",{"date":144,"type":42},"2025-01-29",{"date":146,"type":42},"2024-09-26",{"date":44,"type":21},{"name":149,"class":49},"Centre Hospitalier Universitaire, Amiens",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":176},"100554192","phase-4-pvp-guided-decongestive-therapy-in-hf-2-100554192","NCT06495892","PVP-Guided Decongestive Therapy in HF 2","Peripheral Venous Pressure-Guided Decongestive Therapy in Heart Failure 2","PERIPHERAL-HF2","Inclusion criteria\n\n* Hospitalization for heart failure (de novo or decompensated chronic heart failure) irrespective of left ventricular ejection fraction\n* Age 18-99\n* Accept to participate\n\nExclusion criteria\n\n* A prior history of upper extremity venous disease\n* Serum creatinine ≥ 3.5 mg\u002FdL\n* Severe stenotic valvular disease\n* Hypertrophic obstructive cardiomyopathy\n* Withdrawal of consent\n* Indwelling central venous catheter,\n* Implanted left ventricular assist device\n* History of heart transplantation\n* Clinical diagnosis of cardiogenic shock\n* Any right-to-left shunt","99 Years",{"count":160,"type":21},650,[162],"PHASE4","The investigators hypothesize that a simple assessment of peripheral venous pressure (PVP) will better predict the diuretic need and long-term outcomes (all cause mortality, all cause rehospitalization, emergency department visits) compared to standard evaluation.",[29,28,165],"Congestive Heart Failure","2024-12-01",{"date":168,"type":42},"2024-12-04",{"date":170,"type":42},"2024-07-01",{"date":172,"type":21},"2026-07-01",{"name":174,"class":175},"Başakşehir Çam & Sakura City Hospital","OTHER_GOV",16,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100551431","biomarkers-for-the-assessment-of-congestion-in-patients-with-ambulatory-and-hospitalised-heart-failure-100551431","NCT06459999","Biomarkers for the Assessment of Congestion in Patients With Ambulatory and Hospitalised Heart Failure","BIO-CONGEST","Inclusion Criteria:\n\n* Written informed consent.\n* Male or female ≥18 years of age.\n* Cohort A\n\n  * Meet European Society of Cardiology (ESC) criteria for diagnosis of HF1, including HF with reduced (HFrEF), mildly reduced (HFmrEF) and preserved ejection fractions (HFpEF).\n  * Hospitalised for the management of HF or outpatients.\n  * Undergoing clinically-indicated RHC or repeat clinically-indicated RHC.\n* Cohort B\n\n  * Meet ESC criteria for diagnosis of HFrEF.\n  * Undergoing implantation of CRT device and a simultaneous clinically-indicated RHC.\n* Cohort C\n\n  * Meet ESC criteria for diagnosis of HF, including HFrEF, HFmrEF, HFpEF.\n  * Requiring treatment with IV diuretics.\n\nExclusion Criteria:\n\n* Unwilling to consent.\n* Unable to consent to inclusion in study due to cognitive impairment.\n* Previously enrolled in the BIO-CONGEST study.\n* Current participation in a blinded drug interventional trial (or treatment within four weeks).\n* Pregnancy or breast-feeding (cohorts A + B where applicable).\n* Currently uncontrolled cardiac arrhythmia.\n* Severe aortic valvular disease.\n* Increased body mass index where satisfactory echocardiographic images are not possible.\n* Conditions that may confound congestion assessments in the opinion of the investigator, including: severe obstructive lung disease, severe fibrotic lung disease, severe liver disease, relevant active malignancy including lung cancer, pelvic cancer with caval compression, superior vena cava (SVC) obstruction syndrome, active viral or bacterial bronchopneumonia - chest x-ray (CXR) within four weeks showing consolidation, pulmonary contusion, pneumothorax, pneumonectomy, lobectomy, pulmonary embolism within the previous three months, indwelling intercostal chest drain, left ventricular assist device (LVAD), COVID-19 infection, type-1 acute myocardial infarction.",{"count":185,"type":21},140,"The goal of this study is to test the accuracy of new blood and urine tests in people with heart failure. The main question it aims to answer is:\n\n\\- Do new blood and urine tests correlate with fluid status? This will be determined by comparison to routine and gold-standard tests in a range of patients with heart failure.",[29,28],"2024-06-10",{"date":190,"type":42},"2024-06-14",{"date":192,"type":21},"2024-06",{"date":194,"type":21},"2025-12",{"name":196,"class":49},"NHS Greater Glasgow and Clyde",2]